[EN] ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF<br/>[FR] CONJUGUÉS ANTICORPS-AGONISTES DE TLR, PROCÉDÉS ET UTILISATIONS DE CEUX-CI
申请人:AMBRX INC
公开号:WO2022040596A1
公开(公告)日:2022-02-24
Disclosed herein are TLR-agonists compounds, antibody-TLR agonist conjugates, pharmaceutical composition, and methods of use of such compounds or conjugates as therapeutics for treating a disease or condition such as cancer.
Monomethylvaline Compounds Having Phenylalanine Side-Chain Replacements at the C-Terminus
申请人:Doronina Svetlana O.
公开号:US20090018086A1
公开(公告)日:2009-01-15
Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS
申请人:Seattle Genetics, Inc.
公开号:US20130123465A1
公开(公告)日:2013-05-16
Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus
申请人:Seattle Genetics, Inc.
公开号:US10000555B2
公开(公告)日:2018-06-19
Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) are provided having C-terminal phenylalanine residue side chain replacements or modifications which are provided alone or attached to ligands through various linkers. The related conjugates can target specific cell types to provide therapeutic benefit.
提供的 MeVal-Val-Dil-Dap-Phe (MMAF) Auristatin 肽类似物具有 C 端苯丙氨酸残基侧链替换或修饰,可单独提供或通过各种连接体连接到配体上。相关共轭物可靶向特定细胞类型,提供治疗效果。
Non-natural amino acid replication-dependent microorganisms and vaccines
申请人:Ambrx, Inc.
公开号:US10428333B2
公开(公告)日:2019-10-01
Compositions and methods of producing vaccines, including methods wherein whole organism vaccines are provided with limited replication abilities, thereby increasing vaccine safety and efficacy, through the use of non-natural, unnatural, or non-naturally encoded amino acids.